Chanhold

RSS

selamectin

Authorised
This medicine is authorised for use in the European Union.

Overview

Chanhold is an antiparasitic medicine used to treat and prevent infestations with parasites that live on the skin or in the fur of cats and dogs, such as fleas and mites, as well as treating worm parasites that live inside the body. It is used in the following ways:

  • to treat and prevent flea infestations in cats and dogs, by killing adult fleas, their larvae and their eggs on the animal, and in the litters of pregnant or nursing cats or dogs. It can also be used as part of a treatment for flea allergy dermatitis (skin inflammation),
  • to prevent heartworm disease in cats and dogs,
  • to treat ear mites in cats and dogs,
  • to treat adult intestinal roundworms and intestinal hookworms in cats,
  • to treat adult intestinal roundworms in dogs,
  • to treat biting lice infestations in cats and dogs,
  • to treat sarcoptic mange (scabies) in dogs.

Chanhold contains the active substance selamectin and is a ‘generic medicine’. This means that Chanhold contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the European Union (EU) called Stronghold.

This EPAR was last updated on 26/11/2020

Authorisation details

Product details
Name
Chanhold
Agency product number
EMEA/V/C/004824
Active substance
selamectin
International non-proprietary name (INN) or common name
selamectin
Species
  • Cats
  • Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QP54AA05
Publication details
Marketing-authorisation holder
Chanelle Pharmaceuticals Manufacturing Ltd
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
17/04/2019
Contact address

Dublin Road
Loughrea
Co. Galway
Ireland

Product information

19/11/2020 Chanhold - EMEA/V/C/004824 - IB/0006

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antiparasitic products, insecticides and repellents

Therapeutic indication

Cats and dogs:

Treatment and prevention of flea infestations caused by Ctenocephalides spp. for one month following a single administration. This is as a result of the adulticidal, larvicidal and ovicidal properties of the product. The product is ovicidal for 3 weeks after administration. Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will also aid in the prevention of flea infestations in the litter up to seven weeks of age. The product can be used as part of a treatment strategy for flea allergy dermatitis and through its ovicidal and larvicidal action may aid in the control of existing environmental flea infestations in areas to which the animal has access.

Prevention of heartworm disease caused by Dirofilaria immitis with monthly administration.

The product may be safely administered to animals infected with adult heartworms, however, it is recommended, in accordance with good veterinary practice, that all animals 6 months of age or more living in countries where a vector exists should be tested for existing adult heartworm infections before beginning medication with the product. It is also recommended that dogs should be tested periodically for adult heartworm infections, as an integral part of a heartworm prevention strategy, even when the product has been administered monthly. This product is not effective against adult D. immitis.

Treatment of ear mites (Otodectes cynotis).

Cats:

  • Treatment of biting lice infestations (Felicola subrostratus)
  • Treatment of adult roundworms (Toxocara cati)
  • Treatment of adult intestinal hookworms (Ancylostoma tubaeforme)
  • Treatment of biting lice infestations (Trichodectes canis)
  • Treatment of sarcoptic mange (caused by Sarcoptes scabiei)

Assessment history

How useful was this page?

Add your rating